

Aaron D Bossler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6581790/publications.pdf>

Version: 2024-02-01

41
papers

1,328
citations

430874

18
h-index

361022

35
g-index

44
all docs

44
docs citations

44
times ranked

2634
citing authors

#	ARTICLE	IF	CITATIONS
1	OUP accepted manuscript. American Journal of Clinical Pathology, 2022, , .	0.7	4
2	Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer. Redox Biology, 2022, 53, 102318.	9.0	8
3	Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy. Cancers, 2021, 13, 1489.	3.7	7
4	Validation of Optical Genome Mapping for the Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy. Journal of Molecular Diagnostics, 2021, 23, 1506-1514.	2.8	32
5	PTCH1-GLI1 Fusionâ€“Positive Ovarian Tumor: Report of a Unique Case With Response to Tyrosine Kinase Inhibitor Pazopanib. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 998-1004.	4.9	18
6	Monocytes Exposed to Immune Complexes Reduce pDC Type 1 Interferon Response to Vidutolimod. Vaccines, 2021, 9, 982.	4.4	0
7	CLIA Laboratory Testing for Facioscapulohumeral Dystrophy. Neurology, 2021, 96, e1054-e1062.	1.1	18
8	Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies. Antibiotics, 2020, 9, 740.	3.7	11
9	Exploration of PCORnet Data Resources for Assessing Use of Molecular-Guided Cancer Treatment. JCO Clinical Cancer Informatics, 2020, 4, 724-735.	2.1	8
10	Coactivation of NF-Î²B and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion. Blood, 2020, 135, 108-120.	1.4	14
11	CLL dedifferentiation to clonally related myeloid cells. Blood Advances, 2020, 4, 6169-6174.	5.2	1
12	Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events. Journal of Oncology, 2019, 2019, 1-7.	1.3	15
13	Urothelial carcinoma with an <i>NRF1-BRAF</i> rearrangement and response to targeted therapy. Journal of Physical Education and Sports Management, 2019, 5, a003848.	1.2	9
14	<i>BCR-NTRK2</i> fusion in a low-grade glioma with distinctive morphology and unexpected aggressive behavior. Journal of Physical Education and Sports Management, 2019, 5, a003855.	1.2	19
15	Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma. Melanoma Research, 2019, 29, 643-647.	1.2	13
16	Simultaneous detection of single-nucleotide variant, deletion/insertion, and fusion in lung and thyroid carcinoma using cytology specimen and an RNA-based next-generation sequencing assay. Cancer Cytopathology, 2018, 126, 158-169.	2.4	18
17	Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy. BMC Cancer, 2018, 18, 225.	2.6	28
18	Biallelic TP53 gain of function mutations in rapidly progressing solid tumors. Cancer Genetics, 2018, 222-223, 20-24.	0.4	6

#	ARTICLE	IF	CITATIONS
19	Toxicities with targeted therapies after immunotherapy in metastatic melanoma. <i>Melanoma Research</i> , 2018, 28, 600-604.	1.2	10
20	TRAPPC11 and GOSR2 mutations associate with hypoglycosylation of Î±-dystroglycan and muscular dystrophy. <i>Skeletal Muscle</i> , 2018, 8, 17.	4.2	47
21	A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas. <i>Cancers</i> , 2018, 10, 53.	3.7	16
22	Anchored multiplex PCR for targeted next-generation sequencing reveals recurrent and novel USP6 fusions and upregulation of USP6 expression in aneurysmal bone cyst. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 266-277.	2.8	61
23	Melanoma cells undergo aggressive coalescence in a 3D Matrigel model that is repressed by anti-CD44. <i>PLoS ONE</i> , 2017, 12, e0173400.	2.5	18
24	Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase Ib study. <i>Oncotarget</i> , 2017, 8, 89182-89193.	1.8	33
25	Leukemic Transdifferentiation of Follicular Lymphoma Into an Acute Histiocytic Leukemia in a 52-Year-Old Caucasian Woman. <i>Laboratory Medicine</i> , 2016, 47, 155-157.	1.2	9
26	Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 319-328.	2.8	77
27	The NAB2-STAT6 gene fusion in solitary fibrous tumor can be reliably detected by anchored multiplexed PCR for targeted next-generation sequencing. <i>Cancer Genetics</i> , 2016, 209, 303-312.	0.4	27
28	Germline mutations predisposing to non-small cell lung cancer. <i>Familial Cancer</i> , 2015, 14, 463-469.	1.9	15
29	An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge. <i>Genome Biology</i> , 2014, 15, R53.	9.6	101
30	A simple and cost-effective method of DNA extraction from small formalin-fixed paraffin-embedded tissue for molecular oncologic testing. <i>BMC Clinical Pathology</i> , 2014, 14, 30.	1.8	23
31	Evaluation of the Bruker Biotyper and Vitek MS Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Systems for Identification of Nonfermenting Gram-Negative Bacilli Isolated from Cultures from Cystic Fibrosis Patients. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2034-2039.	3.9	118
32	Performance of the COBAS® AmpliPrep/COBAS TaqMan® automated system for hepatitis C virus (HCV) quantification in a multi-center comparison. <i>Journal of Clinical Virology</i> , 2011, 50, 100-103.	3.1	12
33	Muscle-Eye-Brain Disease. <i>Journal of Clinical Neuromuscular Disease</i> , 2010, 11, 124-126.	0.7	11
34	Conventional and Real-Time Polymerase Chain Reaction. , 2009, , 33-49.		4
35	Interferon-beta treatment increases human papillomavirus early gene transcription and viral plasmid genome replication by activating interferon regulatory factor (IRF)-1. <i>Carcinogenesis</i> , 2009, 30, 1336-1344.	2.8	21
36	Human Papillomavirus (HPV) Type 18 Induces Extended Growth in Primary Human Cervical, Tonsillar, or Foreskin Keratinocytes More Effectively than Other High-Risk Mucosal HPVs. <i>Journal of Virology</i> , 2009, 83, 11784-11794.	3.4	29

#	ARTICLE	IF	CITATIONS
37	Deletion of the PDZ motif of HPV16 E6 preventing immortalization and anchorage-independent growth in human tonsil epithelial cells. <i>Head and Neck</i> , 2008, 30, 139-147.	2.0	45
38	The PDZ Binding Motif of Human Papillomavirus Type 16 E6 Induces PTPN13 Loss, Which Allows Anchorage-Independent Growth and Synergizes with Ras for Invasive Growth. <i>Journal of Virology</i> , 2008, 82, 2493-2500.	3.4	116
39	A novel t(3;8)(q27;q24.1) simultaneously involving both the BCL6 and MYC genes in a diffuse large B-cell lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 2007, 172, 45-53.	1.0	21
40	Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma. <i>Journal of Immunotherapy</i> , 2006, 29, 558-568.	2.4	145
41	Novel mutations in <i>ENG</i> and <i>ACVRL1</i> identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype. <i>Human Mutation</i> , 2006, 27, 667-675.	2.5	136